ONTX Key Statistics, Chart & Performance
The current stock price of ONTX is 0.9953 USD. In the past month the price increased by 7.02%. In the past year, price increased by 42.19%.
ONTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ONTX. When comparing the yearly performance of all stocks, ONTX is one of the better performing stocks in the market, outperforming 91.64% of all stocks.
ONTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONTX. ONTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ONTX Financial Highlights
Over the last trailing twelve months ONTX reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS decreased by -21.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.67% | ||
| ROE | -139.07% | ||
| Debt/Equity | 0 |
ONTX Forecast & Estimates
9 analysts have analysed ONTX and the average price target is 8.5 USD. This implies a price increase of 754.01% is expected in the next year compared to the current price of 0.9953.
For the next year, analysts expect an EPS growth of -7.23% and a revenue growth 2.54% for ONTX
ONTX Ownership
ONTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.97 | 976.55B | ||
| JNJ | JOHNSON & JOHNSON | 21.15 | 529.01B | ||
| MRK | MERCK & CO. INC. | 12.6 | 275.43B | ||
| PFE | PFIZER INC | 8.09 | 147.20B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.63 | 115.26B | ||
| ZTS | ZOETIS INC | 19.76 | 55.21B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.66 | 22.93B | ||
| VTRS | VIATRIS INC | 5.51 | 14.79B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.19 | 12.01B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.78B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.22B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.35B |
Related stock screener links
About ONTX
Company Profile
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 16 full-time employees. The company went IPO on 2013-07-25. The company has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. The company has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib targets cyclin-dependent kinases (CDK's), AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R) at low nM concentrations as well as other tyrosine kinases. The company is also engaged in supporting investigator-initiated studies (IIS) that explores the use of rigosertib for cancers driven by mutated K-Ras genes, including a Phase I/IIa study of rigosertib with a PD-1 inhibitor.
Company Info
ONCONOVA THERAPEUTICS INC
375 Pheasant Run
Newtown PENNSYLVANIA 18940 US
CEO: Steven M. Fruchtman
Employees: 16
Phone: 12677593681
ONCONOVA THERAPEUTICS INC / ONTX FAQ
Can you describe the business of ONCONOVA THERAPEUTICS INC?
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 16 full-time employees. The company went IPO on 2013-07-25. The company has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. The company has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib targets cyclin-dependent kinases (CDK's), AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R) at low nM concentrations as well as other tyrosine kinases. The company is also engaged in supporting investigator-initiated studies (IIS) that explores the use of rigosertib for cancers driven by mutated K-Ras genes, including a Phase I/IIa study of rigosertib with a PD-1 inhibitor.
What is the current price of ONTX stock?
The current stock price of ONTX is 0.9953 USD. The price decreased by -0.47% in the last trading session.
Does ONCONOVA THERAPEUTICS INC pay dividends?
ONTX does not pay a dividend.
How is the ChartMill rating for ONCONOVA THERAPEUTICS INC?
ONTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is ONCONOVA THERAPEUTICS INC worth?
ONCONOVA THERAPEUTICS INC (ONTX) has a market capitalization of 20.90M USD. This makes ONTX a Nano Cap stock.